Factors Outside Amyloid and Brain-Body Communication in Alzheimer's Disease and Future Treatments

AD is a progressive neurodegenerative disorder and the predominant etiology of dementia worldwide [9]. Currently, over 55 million individuals globally are living with dementia, a prevalence projected to surpass 152 million by 2050 as a direct consequence of an aging global demographic [10]. In the United States alone, the disease affects nearly 7 million adults aged 65 and older, constituting a critical public health crisis associated with a profound socioeconomic burden [11].

Crucially, “pure” AD pathology is increasingly recognized as the clinical exception rather than the rule. The condition frequently presents as “mixed dementia,” characterized by a complex interplay with cerebrovascular disease [12]. Prevalent systemic comorbidities—most notably hypertension, type 2 diabetes mellitus, and broad cardiovascular disease—significantly exacerbate neurovascular unit dysfunction and accelerate the trajectory of cognitive decline [13]. Furthermore, neuropsychiatric comorbidities, including depression, apathy, and anxiety, frequently manifest during the prodromal and early clinical stages, functioning dually as core phenotypic features and catalysts for further deterioration [14]. However, a profound discrepancy exists between this epidemiological reality and contemporary clinical trial design. While population data confirm that AD overwhelmingly co-occurs with vascular and metabolic comorbidities, pivotal disease-modifying therapy (DMT) trials systematically exclude these exact patients to isolate pure amyloid pathology [15]. Consequently, a massive translational knowledge gap remains regarding the safety and efficacy of emerging biologics in the highly comorbid, real-world aging population.

The clinical progression of AD entails a relentless deterioration across multiple cognitive domains. This typically initiates with episodic memory deficits before advancing to profoundly impair executive function, visuospatial processing, and language capabilities [16]. Such cognitive erosion directly translates into severe functional disability, systematically compromising the patient’s capacity to execute both basic Activities of Daily Living (ADLs)—such as dressing and feeding—and more complex Instrumental Activities of Daily Living (IADLs), such as managing finances, medication, or transportation. To accurately evaluate and monitor this trajectory of cognitive impairment and neurodegeneration, clinical practice relies heavily on widely used standardized clinical assessment tools. Specifically, the Mini-Mental State Examination (MMSE) serves as a foundational instrument for quantifying global cognitive decline, while validated ADL and IADL scales are explicitly utilized to stage the severity of real-world functional loss. This progressive loss of autonomy, invariably compounded by behavioral and psychological symptoms of dementia (BPSD), imposes a devastating emotional, physical, and financial toll on caregivers, underscoring the urgent imperative for holistic care models [17].

The epidemiological landscape of AD is notably heterogeneous. Although advancing age remains the primary risk factor, sex and race function as critical disease stratifiers [11]. Women account for approximately two-thirds of all AD cases; this prevalence disparity is only partially attributable to greater female longevity, pointing toward unique biological, metabolic, and neuroendocrinological vulnerabilities [11]. As highlighted by Andrew and Tierney [18], the etiology of this sex-based disparity is highly complex and cannot be reduced to a simple survival artifact. Instead, it is driven by an intersection of biological vulnerabilities and sociocultural determinants, including the profound metabolic shifts associated with the menopausal transition—which abruptly deprives the central nervous system of estrogen’s neuroprotective and bioenergetic support. Additionally, women historically exhibit differences in the accumulation of cognitive reserve and demonstrate higher rates of multidimensional frailty at equivalent ages compared to men, all of which lower the clinical threshold for dementia manifestation [18].

Furthermore, racial and ethnic minorities exhibit markedly divergent incidence rates. Specifically, older Black Americans are approximately twice as likely, and older Hispanic Americans are about one and a half times as likely, to develop AD compared to older non-Hispanic White populations [11]. These disparities are driven by a confluence of compounding factors, including higher burdens of cardiovascular comorbidities and structurally differential access to care [11]. Despite bearing this substantially higher relative risk, Black and Hispanic populations remain chronically underrepresented in neuroimaging, fluid biomarker, and genomic research, frequently comprising less than 5% of pivotal Phase 3 trial cohorts [19,20]. This creates a dangerous void in our understanding of how the ATN(I) biomarker framework, Apolipoprotein E gene (APOE) ε4 penetrance, and DMT safety profiles (such as ARIA risk) manifest across diverse genetic and socioeconomic backgrounds.

The etiology of AD is further modulated by a complex interplay of genetic predispositions and environmental exposures. While the APOE ε4 allele remains the most potent genetic risk modifier, an estimated 40% of dementia cases worldwide are attributable to modifiable risk factors [21]. The Lancet Commission has delineated a life-course model detailing these targets, encompassing early-life educational attainment, mid-life hearing loss, hypertension, and obesity, alongside late-life factors such as depression, physical inactivity, diabetes mellitus, and social isolation [21]. Nevertheless, a distinct mechanistic disconnect persists in current research. While epidemiological models attribute a massive 40% of dementia risk to these modifiable factors [21], there is a glaring lack of longitudinal data directly linking these systemic exposures to the molecular acceleration of amyloid, tau, and neuroinflammation. Bridging the gap between macro-level public health interventions and micro-level biomarker validation remains a critical priority for future preventative trial designs [22].

Alzheimer’s disease is classically defined by the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles; however, conceptualizing these proteinopathies merely as parallel events is an oversimplification. Rather, Aβ and tau drive a synergistic, multi-cellular cascade ultimately culminating in profound synaptic failure—a disruption of neurotransmission and synaptic plasticity that serves as the most direct structural correlate of cognitive decline [23]. Furthermore, the progressive deterioration of these neural networks underscores the necessity of moving beyond amyloid-centric models to address the broader bioenergetic and synaptic collapse defining the disease state.

The pathogenic cascade is largely initiated by the aberrant processing of the amyloid precursor protein (APP), generating soluble Aβ oligomers. Crucially, it is these highly mobile oligomers, rather than insoluble plaques, that are now recognized as the primary neurotoxic species. They directly disrupt synaptic signaling and plasticity, precipitating early synaptic failure well before overt neuronal apoptosis occurs [24]. Beyond direct synaptotoxicity, Aβ oligomers act as potent inflammatory stimuli, triggering pathological microglial and astrocytic activation. This establishes a maladaptive neuroinflammatory milieu that not only exacerbates neuronal injury but also severely compromises intrinsic Aβ clearance mechanisms, locking the brain into a self-perpetuating cycle of toxicity [25].

A fundamental pillar of this clearance infrastructure is the glymphatic system, a brain-wide paravascular pathway for waste clearance. This system is facilitated by Aquaporin-4 (AQP4) water channels located on astrocytic endfeet, which allow the exchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF) to flush out neurotoxic proteins such as Aβ and tau. When this clearance interface is compromised, Aβ serves as a critical upstream trigger for tau pathology, which is widely considered the primary executioner of neurodegeneration [26].

In the AD milieu, a critical imbalance between kinase and phosphatase activity drives aberrant tau hyperphosphorylation. This causes tau to dissociate from microtubules and self-assemble into toxic intracellular tangles, effectively dismantling axonal transport corridors. Notably, the spatiotemporal progression of tau pathology—unlike Aβ plaque burden—exhibits a robust and direct correlation with the severity of cognitive impairment [27]. Synaptic dysfunction serves as the critical convergence point where Aβ and tau pathologies synergistically dismantle neural networks. Compelling evidence demonstrates that tau acts as an essential downstream mediator of Aβ-induced synaptotoxicity; without dendritic tau, the deleterious effects of Aβ oligomers are significantly blunted [28].

Emerging evidence supports a profound, bidirectional pathophysiological relationship between AD and peripheral neuropathies. Historically compartmentalized as anatomically distinct disorders, these conditions are now recognized as interconnected manifestations of systemic neuroinflammation.

Mitochondrial dysfunction is a primary, initiating driver of systemic neuronal vulnerability. Impairments in bioenergetics, compromised calcium homeostasis, and elevated reactive oxygen species (ROS) act synergistically to precipitate early synaptic failure [38]. Because axons possess massive metabolic demands yet limited regenerative capacities, accumulating Aβ oligomers and hyperphosphorylated tau catastrophically disrupt the bidirectional transport of mitochondria [39]. Consequently, mitochondria fail to reach distal synaptic terminals.

Critically, because peripheral neurons possess exceptionally long axons and lie outside the protective blood–brain barrier (BBB) [40], they are highly susceptible to the systemic inflammatory mediators and metabolic stressors that drive this transport failure [41]. This anatomical vulnerability suggests that peripheral nerve damage is not merely a parallel comorbidity, but can serve as an early, clinically accessible indicator of central neurodegenerative processes. The local energy crisis that drives the retrograde “dying-back” axonopathy observed in peripheral neuropathies perfectly mirrors—and may clinically precede—the large-scale network disconnection characteristic of advanced AD [42]. Therefore, the manifestation of peripheral neuropathy provides a vital diagnostic window into the systemic mitochondrial collapse and neuroinflammation that are simultaneously threatening the central nervous system.

The genetic architecture of AD is fundamentally divided into early-onset (EOAD) and late-onset (LOAD) forms, each dictated by distinct pathogenic trajectories [62]. This architecture is deeply complex, necessitating a nuanced understanding of genotype–phenotype correlations, zygosity effects, penetrance, and expressive variability. EOAD, which accounts for a small minority of cases (typically presenting before age 65), is primarily driven by highly penetrant, autosomal dominant mutations in the amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes. In these familial cases, the genetic defect alone is usually sufficient to aggressively drive early amyloidosis and disease onset. However, clinical penetrance and phenotypic expressivity can vary significantly even among individuals harboring the same mutation [63].

To provide a rigorous, multi-scale overview of these distinct genetic architectures, Table 1 details the primary genetic determinants implicated in both EOAD and LOAD. This comprehensive compilation explicitly charts their chromosomal localizations, official Online Mendelian Inheritance in Man (OMIM) associations, core disease classifications, and the profound phenotypic variability observed in clinical practice.

Furthermore, the genetic boundaries between distinct neurodegenerative syndromes are increasingly recognized as fluid. For instance, while hexanucleotide repeat expansions in the C9orf72 gene are classically associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), recent literature has increasingly reported their association with AD-like clinical phenotypes, highlighting the pleiotropic nature of dementia genetics [64].

To unravel this intricate genetic landscape and identify individuals at risk of early-onset cognitive impairment, modern Next-Generation Sequencing (NGS) diagnostic approaches have become indispensable in clinical and research settings. Techniques such as Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), and targeted gene panels provide high-resolution mapping of both rare pathogenic variants and complex polygenic risk profiles. These advanced genomic tools are crucial for comprehensively understanding the genetic architecture of AD, enabling early diagnostic stratification and facilitating precision-medicine therapeutic trials [65,66].

While autosomal dominant mutations dictate the aggressive onset of familial disease, the polygenic risk factors underlying sporadic LOAD function quite differently—they do not act as independent determiners but rather establish the baseline physiological vulnerability required for subsequent gene–environment interactions. For example, the APOE ε4 allele remains the most potent genetic risk modifier for LOAD, where zygosity exerts a profound effect: homozygous APOE ε4 carriers exhibit a significantly accelerated age of onset and a more aggressive clinical phenotype compared to heterozygotes [67].

In contrast, the vast majority of AD cases are late-onset and polygenic. The etiology of AD is a synergistic convergence of heritable susceptibility and environmental exposures. This convergence occurs when specific genetic vulnerabilities—most notably the APOE ε4 allele, alongside variants in neuroimmune and lipid-regulating genes such as Triggering receptor expressed on myeloid cells 2 (TREM2), or ATP-binding cassette subfamily A member 1 (ABCA1)—interact with chronic external stressors (such as obesogenic diets, neurotoxins, or chronic infections) to produce a compounded pathogenic outcome that neither factor could achieve as rapidly on its own [81]. For instance, while the APOE ε4 allele severely impairs central amyloid clearance, it simultaneously exacerbates peripheral microvascular degradation by disrupting lipid recycling [82]. When an APOE ε4 carrier is exposed to an obesogenic diet, these factors synergize to drive severe systemic insulin resistance and systemic cytokine storms (e.g., IL-1β, IL-18).

This dynamic perfectly illustrates the “double-hit” hypothesis: a physiological baseline compromised by genetic susceptibility (the first hit) requires the compounding insult of chronic environmental or metabolic stress (the second hit) to cross the threshold into irreversible neurodegeneration (Figure 3) [83]. This complex gene–environment reality exposes a critical limitation in contemporary research. While single-mutation transgenic murine models (e.g., isolated APP mutations) have been undeniably invaluable for isolating specific molecular pathways of amyloid cleavage, they fundamentally fail to replicate the systemic “double-hit” interactions seen in human AD [84]. In human patients, polygenic vulnerability collides with decades of vascular disease, inflammaging, and metabolic syndrome. Consequently, preclinical success in highly controlled models rarely translates to clinical efficacy, highlighting an urgent need for multi-morbidity animal models that accurately reflect the human systemic aging process.

The diagnostic paradigm for AD has fundamentally shifted from a symptom-based, clinico-pathological framework to a biologically defined construct. This transition is formalized in the ATN (Amyloid, Tau, and Neurodegeneration) research framework, which utilizes continuous fluid and imaging biomarkers to define the disease state across its preclinical and clinical spectrum, independent of cognitive symptomatology [86]. The rapid integration of ultra-sensitive fluid markers with advanced neuroimaging currently allows for unprecedented precision in early detection, patient stratification, and longitudinal monitoring.

While AD is classically defined by central nervous system (CNS) pathology, a robust and expanding body of evidence dictates that the peripheral nervous system (PNS) is concurrently compromised. These peripheral manifestations, frequently presenting as subclinical sensory and motor neuropathies, often precede or parallel cognitive decline [104]. Consequently, assessing the PNS in AD cohorts provides an accessible, in vivo “window” into systemic axonal health, leveraging electrophysiological, morphological, and serological diagnostics to map the true systemic extent of neurodegeneration (Figure 4).

The inherent pathophysiological complexity of AD necessitates a paradigm shift from a monolithic, symptom-based diagnostic model to a dynamic, multi-modal biological framework. The NIA-AA ATN framework provided the initial scaffolding for defining AD biologically in vivo [86]. However, critical evaluations of this model note its limitations in capturing the systemic heterogeneity of the disease. Recognizing this, recent iterations have formally expanded to include inflammatory (I) indices, reflecting a vital shift toward an ATN(I) or broader ATN(X) framework capable of capturing systemic immune dysregulation [96,114]. To fully bridge central neurodegeneration with peripheral nerve dysfunction, this must be conceptually expanded further to an integrative ATN(I)(M) model, incorporating metabolic (M) markers.

The standard ATN profile establishes the core biological presence of AD. Amyloid positivity (A+), determined via PET or plasma ratios, represents the initiating biological state, while Tau positivity (T+) signifies the active disease stage and correlates with classic amnestic phenotypes [86]. Neurodegeneration (N+), marked by elevated NfL or structural atrophy, reflects cumulative downstream injury. Consequently, an A+T+N+ profile strongly predicts the classic trajectory of rapid-onset, multidomain dementia, whereas an A+T-N- profile indicates early pathologic change, delineating a critical window for preventative intervention [96].

Beyond the core proteins, the trajectory of cognitive decline is heavily modulated by the innate immune response (the Inflammatory Axis). Fluid biomarkers such as plasma glial fibrillary acidic protein (GFAP) and soluble TREM2 (sTREM2) serve as proxies for reactive astrocytosis and microglial activation [115]. Patients presenting with elevated inflammatory markers (I+) alongside core AD pathology frequently exhibit a “rapid progressor” clinical phenotype, as unresolved neuroinflammation accelerates synaptic pruning [116]. Integrating the Metabolic Axis (M)—such as indices of insulin resistance (Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)) and lipidomic profiles—further identifies patients with a “mixed” phenotype. Clinically, an ATN+ Metabolic (M+) profile manifests early as gait disturbances, motor slowing, and small-fiber peripheral neuropathy [117]. By evolving from a binary diagnostic label to a multidimensional narrative ATN(I)(M) profile, clinicians can effectively deconstruct the heterogeneous presentation of AD to guide highly personalized interventions.

The clinical manifestation of Alzheimer’s disease (AD) and its associated neuropathies can no longer be viewed as a monolithic, central nervous system (CNS)-isolated syndrome. Rather, it represents a continuous, multisystem spectrum of neurological dysfunction. As outlined in recently updated diagnostic frameworks [86,96], accurate patient stratification via this biological continuum is the requisite foundation for selecting mechanism-driven, personalized therapies. The distinct trajectories and differential diagnoses of these AD clinical phenotypes are synthesized in Table 3.

Moving from clinical manifestations to their molecular underpinnings requires abandoning the outdated, monolithic amyloid cascade hypothesis. The clinical heterogeneity of AD can only be understood through precise phenotype–mechanism correlations that view the body as an integrated system. A critical advancement in this domain is the recognition of a bidirectional “biological bridge” between the CNS and the peripheral nervous system (PNS) [128]. While the classical amnestic phenotype correlates neatly with the spatiotemporal spread of tau pathology, patients exhibiting the “mixed” phenotype reveal a different underlying reality driven by two primary shared vulnerabilities: systemic inflammatory crosstalk and bioenergetic failure [127].

Chronic activation of the innate immune system—specifically, pathological microglial activation in the brain and macrophage infiltration in peripheral nerves—creates a systemic cytokine storm. This circulating inflammatory burden degrades the structural integrity of both the blood–brain barrier (BBB) and the blood-nerve barrier (BNB) [129]. Consequently, toxic oligomers and inflammatory mediators circulate freely between compartments, driving synergistic degenerative processes across the entire neuro-axis. Concurrently, the central and peripheral nervous systems share a critical reliance on massive, uninterrupted energy supplies. Systemic metabolic failures trigger a devastating dual-compartment energy crisis [130]. This glucose hypometabolism simultaneously starves the hippocampus—impairing synaptic plasticity—and disrupts the highly energy-intensive, long-distance axonal transport essential for PNS maintenance, leading directly to distal “dying back” neuropathies [131,132,133].

To conceptualize these interconnected pathological events, Figure 5 provides a comprehensive visual summary of this CNS–PNS “biological bridge.” The schematic illustrates how shared systemic triggers—such as metabolic failure, inflammaging, and gut dysbiosis—converge to initiate a massive systemic cytokine storm and a dual-compartment bioenergetic crisis. This central hub of systemic vulnerability subsequently drives the parallel degradation of the blood–brain barrier (BBB) and blood–nerve barrier (BNB). By mapping the concurrent activation of central microglia and peripheral macrophages alongside the infiltration of toxic oligomers, the figure highlights how these shared mechanisms result in both hippocampal starvation and distal axonal transport disruption, ultimately culminating in synergistic neurodegeneration across the entire neuro-axis.

The historical conceptualisation of AD as a homogenous clinic-pathological entity has been definitively superseded by a precision medicine paradigm. Recognizing and mapping phenotype–mechanism correlations is now the absolute cornerstone of modern translational neuroscience. The clinical reality is that the rate of cognitive decline is heavily dictated by concurrent co-pathologies, including α-synuclein, TDP-43, and cerebrovascular disease, rendering the concept of “pure AD” virtually obsolete in aging populations [32].

Yet, a glaring translational controversy lies in the stark disconnect between this recognized phenotypic heterogeneity and contemporary clinical trial design. While precision medicine dictates targeting specific mechanisms, current pivotal Phase 3 trials for anti-amyloid monoclonal antibodies—such as the Clarity AD trial for lecanemab (NCT03887455↗) and the TRAILBLAZER-ALZ 2 trial for donanemab (NCT04437511↗)—rigidly enforce homogeneous inclusion criteria [134]. By aggressively screening out patients with significant vascular, metabolic, or mixed pathologies, the field systematically excludes the vast majority of patients who exhibit complex, metabolically driven phenotypes. Consequently, we risk approving therapeutics whose efficacy and safety profiles are entirely unknown for the average, real-world AD patient. Integrating detailed phenotypic data with specific biomarker profiles ensures that individuals whose phenotypes are heavily driven by systemic inflammatory or metabolic dysfunctions are directed toward targeted interventions, avoiding inappropriate funneling into broadly applied anti-amyloid monotherapies.

The therapeutic landscape for AD is finally beginning to reflect the biological complexity outlined in previous chapters. The paradigm is shifting from purely symptomatic management to disease-modifying therapies (DMTs) that attempt to alter underlying pathophysiological trajectories. Treatment strategies are currently stratified into symptomatic agents and DMTs, with the latter aggressively targeting Aβ clearance, tau propagation, and broader systemic metabolic pathways, as depicted in Figure 6.

To effectively alter the disease course, therapeutics must treat AD and its associated peripheral neuropathies as interconnected disorders. Achieving this requires a comprehensive, multi-modal strategy encompassing systemic immune modulation, metabolic restoration, and advanced gene-targeted interventions. The specific mechanisms driving these emerging molecular approaches—including the RNA- and DNA-targeted therapies illustrated subsequently in Figure 7—will be explored in detail throughout the following subsections.

Neuroinflammation is an active driver bridging central cognitive decline and peripheral nerve damage [144]. Through a compromised BBB, central cytokines (TNF-α, IL-1β) spill into the periphery, while systemic signals recruit peripheral macrophages into the CNS [145,146]. Modern targeted therapies aim at the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome—a universal trigger for this cytokine storm—to simultaneously extinguish the inflammatory response in both central networks and peripheral nerve beds [147].

Furthermore, metabolic therapy directly addresses the profound, localized insulin resistance in the AD brain, a phenotype that structurally mirrors the metabolic starvation seen in diabetic peripheral neuropathy. Glucagon-like peptide-1 (GLP-1) receptor agonists represent a massive breakthrough in neuroprotective strategy; these agents cross the BBB to enhance mitochondrial biogenesis and resensitize insulin signaling [148]. Despite immense epidemiological promise, skeptics question whether GLP-1 agonists exert direct neuroprotective effects on the brain, or if their cognitive benefits are merely secondary artifacts of systemic weight loss and improved peripheral glycemic control. Ongoing Phase 3 trials must definitively untangle this systemic versus central efficacy.

Gene-targeted approaches intervene directly at the genetic source. As illustrated in Figure 7, ASOs facilitate post-transcriptional gene silencing by recruiting RNase H to degrade target pre-mRNA (e.g., microtubule-associated protein tau (MAPT)), halting the synthesis of toxic tau proteins before aggregation occurs [138]. Alternatively, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 enables permanent genomic modification via guide RNA (gRNA)-directed double-strand breaks, offering a theoretical pathway to replace a high-risk apolipoprotein E (APOE) ε4 sequence with the protective APOE ε2 variant in vivo [149]. Yet, the severe ethical and safety risks of irreversible genomic editing in the aging brain—combined with the high potential for off-target mutations and the immense challenge of safe viral vector delivery across the BBB—currently keeps CRISPR confined to theoretical models rather than late-onset AD applications.

The advent of early-stage DMTs has necessitated a transition to mechanism-driven precision medicine, where therapeutic selection is predicated on the dominant biological drivers identified in vivo via the patient’s specific biomarker profile. For amyloid-positive (A+) patients, clearing the initiating trigger is paramount; lecanemab and donanemab selectively bind and clear amyloid via microglial phagocytosis, though evidence confirms this aggressive debulking is clinically beneficial only in the earliest stages, before tau propagation becomes irreversible [7,19].

Conversely, for tau-positive (T+) patients, clearing amyloid is insufficient to stop cognitive decline. Targeting the tau axis is required to stop pathological spread; a Phase 1b trial of the tau-targeting ASO BIIB080 demonstrated a remarkable, dose-dependent reduction in CSF total tau, offering a critical advance for phenotypes actively driven by self-propagating pathology [150]. Furthermore, patients exhibiting a combined central hypometabolism and peripheral neuropathy phenotype require targeted interventions along the Metabolic Axis. While definitive Phase 3 AD trials for GLP-1 agonists are ongoing, post hoc analyses of cardiovascular trials indicate a significantly reduced incidence of dementia in long-term users [151]. Finally, for patients with a high systemic inflammatory load (elevated GFAP or sTREM2), modulating the innate immune response is essential. Small-molecule inhibitors of NLRP3 hold the distinct promise of simultaneously arresting the central cytokine storm and mitigating neuropathic pain pathways in the PNS [152].

Ultimately, the future of neurodegenerative treatment lies in combination therapy. A patient will likely receive an intensive anti-amyloid induction regimen to rapidly “clean” the brain of initiating plaques, followed by a lifelong metabolic and inflammatory maintenance therapy (e.g., GLP-1 agonists) to ensure systemic neuronal resilience, supplemented by an anti-tau agent to prevent further cortical spread (Figure 8).

However, a massive regulatory and financial controversy shadows this future. Currently, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require isolated efficacy data for drug approval [153]. This requirement makes it logistically and financially unfeasible for pharmaceutical companies to test multiple patented, high-cost biologicals in combination trials. Until regulatory frameworks adapt to an oncology-style combination model, this optimal therapeutic strategy remains paralyzed.

The recent success of pivotal Phase 3 clinical trials targeting the amyloid cascade has definitively validated the use of neuroimaging and fluid markers as active pharmacodynamic indicators of therapeutic efficacy [19,20,86].

The validation of biological markers as surrogate clinical endpoints has fundamentally and irreversibly altered the regulatory landscape of AD therapeutics. The modern paradigm demands the integration of high-resolution neuroimaging and advanced fluid assays to provide objective in vivo evidence of both target engagement and downstream disease modification.

The clinical implementation of DMTs has abruptly transitioned from a theoretical ideal to a logistical and ethical crucible that fundamentally challenges current healthcare infrastructures. A primary limitation of the precision medicine paradigm is the profound disparity in access to advanced neuroimaging and fluid assays. The strict reliance on PET imaging creates a severe diagnostic bottleneck. Ethically, this paradigm risks transforming Alzheimer’s disease modification into a privilege exclusive to well-resourced tertiary academic centers, drastically exacerbating global health inequalities [160].

Furthermore, the detection and management of ARIA present a profound ethical dilemma. The controversy lies in the fundamental paradox of modern DMTs: treating a mildly symptomatic, functionally independent patient with a biologic agent that carries a distinct risk of causing life-threatening iatrogenic complications [136,157]. This places the neuroradiologist at the center of the ethical debate and highlights an ongoing controversy regarding the true clinical value of these therapies. Health economists and clinicians alike debate whether the staggering financial cost of the drug, paired with the massive resource burden of serial safety MRIs and PET scans, is justified by the marginal gains in a patient’s daily quality of life [161].

Finally, the shift toward a purely biological definition of AD inherently allows for diagnosis in the preclinical, entirely asymptomatic stage. This introduces a profound ethical minefield regarding the psychological trauma of delivering a molecular diagnosis of a terminal neurodegenerative disease to a cognitively normal individual, often years before symptoms manifest [162]. This controversial reality demands a massive shift toward robust, mandatory psychological counseling frameworks—particularly because early-stage preventative interventions remain largely investigational, leaving asymptomatic patients with a devastating diagnosis but no immediately actionable cure [163].

The therapeutic landscape for AD is finally—and rapidly—expanding beyond the restrictive confines of the traditional amyloid cascade hypothesis to embrace the multifactorial, systemic nature of the disease. Current translational research is heavily pivoting toward emerging molecular targets that capture the systems-level collapse of the AD brain. As outlined in the strategic roadmap in Figure 9, therapeutic development must move beyond isolated protein clearance to actively address neuroinflammation, restore endolysosomal waste clearance, and correct lipid metabolism deficits [135].

The pathophysiological landscape of AD is increasingly understood as a systems-level collapse of cellular and network integrity. Capturing this complexity requires upgrading our analytical tools by integrating multi-omic profiling (e.g., single-cell transcriptomics) with advanced computational modeling [170,171].

To accelerate the development of robust, disease-modifying therapies, future research frameworks must revolutionize clinical execution by prioritizing biomarker integration, target diversification, and cohort inclusivity. Clinical trials must permanently transition away from symptom-based enrolment toward strictly biomarker-driven, preclinical, or early-symptomatic cohorts utilizing the expanded ATN(I) framework. The rigorous validation of scalable fluid markers (particularly plasma p-tau217 and GFAP) will democratize trial access and enable real-time tracking of target engagement [175]. Crucially, this biomarker integration must move beyond strictly neurocentric models. To achieve truly comprehensive trial enrollment, current frameworks must be further expanded to include peripheral and vascular metrics. The integration of emerging precision diagnostics, such as sPDGFRβ for detecting early blood–brain barrier (BBB) breakdown and pericyte injury [45], provides a critical opportunity to stratify patients based on their specific systemic and neurovascular profiles. Identifying these early vascular deficits before irreversible network disconnection occurs will allow researchers to target specific patient subsets with precisely tailored interventions. Furthermore, trial infrastructures must evolve to support adaptive designs capable of evaluating sequential combination therapies. Testing a potent anti-amyloid “induction” phase followed by a neuroprotective or tau-targeting “maintenance” regimen is biologically essential to address the multifactorial nature of the disease.

A glaring imperative for future clinical research is the inclusive enrolment of underrepresented racial, ethnic, and socioeconomic populations. Historically homogeneous trial cohorts severely compromise the generalizability of safety and efficacy data. This represents a profound scientific and ethical controversy: approving biologicals based on cohorts that fundamentally fail to reflect the demographics actually bearing the burden of the disease. For context, older Black and Hispanic populations in the United States are approximately 2 times and 1.5 times more likely to develop AD than older White populations, respectively [11]. Despite this, they are chronically excluded from pivotal data. In the global Phase 3 Clarity AD trial for lecanemab (1795 participants), only 47 participants (2.5%) were Black, and 215 (12%) were Hispanic [19]. Within the U.S.-specific enrolment for that trial, Black participants accounted for merely 4.5%, despite comprising roughly 14% of the U.S. population and over 20% of the U.S. AD demographic [11]. Researchers must aggressively leverage decentralized trial methodologies, digital cognitive phenotyping, and community-based participatory research to close this gap and ensure emerging therapies are safe and effective for all populations [120].

Beyond molecular and pharmacological targets, a comprehensive disease management strategy must incorporate holistic, non-pharmacological lifestyle interventions. Physical activity has emerged as a potent therapeutic consideration, demonstrating significant potential to improve underlying metabolic mechanisms, reduce systemic oxidative stress, and enhance the overall psychological well-being of patients [176]. Similarly, targeted dietary interventions and nutritional modifications play a profound role in altering AD trajectories. These dietary shifts are particularly vital for their direct modulation of the microbiota–gut–brain axis, helping to restore microbial balance, reduce intestinal hyperpermeability, and mitigate systemic inflammaging [177,178]. Finally, the emerging branch of sleep medicine offers critical therapeutic value; given sleep’s fundamental role in facilitating glymphatic waste clearance and maintaining cognitive homeostasis, targeted sleep interventions are essential for slowing AD progression [179]. Ultimately, integrating these clinically relevant lifestyle and metabolic interventions alongside advanced molecular pharmacotherapies will be vital for achieving truly complete, multidimensional disease management.

The era of viewing AD as a localized, intractable proteinopathy has definitively ended. As synthesized in this review, the advent of anti-amyloid disease-modifying therapies validates plaque clearance as a critical pharmacological target, yet simultaneously exposes the severe limitations of monotherapy. Here, the field confronts its most glaring translational controversy: the juxtaposition of undeniable biological target engagement (plaque clearance) against stubbornly marginal clinical cognitive gains and the profound radiological burden of Amyloid-Related Imaging Abnormalities (ARIA). This underscores a fundamental truth: amyloid clearance is merely an induction phase, not a standalone cure.

Mechanistically, AD must now be aggressively targeted as a systemic collapse of the central and peripheral nervous system axis, heavily driven by chronic neuroinflammation, endolysosomal failure, and metabolic starvation. Translating these complex mechanistic insights into real-world clinical utility requires an uncompromising commitment to the expanded ATN(I) biomarker framework. We must strictly utilize advanced neuroimaging and scalable fluid assays (e.g., plasma p-tau217) to guide precision interventions long before irreversible neurodegeneration occurs. Ultimately, the future of AD management dictates a highly targeted, sequential combination approach—pairing early amyloid “debulking” with long-term metabolic and neuroimmune maintenance therapies. By diversifying our molecular targets and mandating equitable, biomarker-driven clinical trial designs, the medical community can finally transform Alzheimer’s from a terminal decline into a manageable, chronic condition.

For both research and clinical practice, the immediate path forward demands a definitive departure from single-target paradigms.

The primary takeaway for investigators is the urgent need to diversify the therapeutic pipeline. Future investigations must evaluate sequential combination therapies—pairing amyloid clearance with agents that target systemic neuroinflammation, endolysosomal repair, and metabolic dysfunction. Furthermore, clinical trials must enforce strict biomarker-driven enrollment while aggressively prioritizing historically underrepresented populations. A critical tension remains here: balancing the need for rigorous, biologically homogenous trial cohorts with the ethical mandate to test drugs on the diverse, multi-morbid populations who actually represent the real-world AD demographic.

In the clinic, the landscape has permanently shifted toward proactive precision medicine. Clinicians and neuroradiologists must tightly integrate advanced fluid biomarkers with high-resolution MRI protocols not only to confirm molecular pathology early but to rigorously mitigate life-threatening complications like ARIA. However, this proactive shift triggers a massive health-economics controversy: global healthcare systems are currently entirely unequipped—financially, logistically, and in terms of a specialized workforce—to support the serial neuroimaging, specialist infusions, and intense monitoring required to safely administer these therapies to millions of aging patients.

Ultimately, conquering Alzheimer’s disease requires intervening during the preclinical window and managing it continuously as a complex, multi-systemic condition, successfully shifting the paradigm from symptom palliation to lifelong biological preservation.